ReviewAnnals of translational medicine2017
Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective.
Review in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- A machine learning framework combining cfDNA fragmentomics and serum biomarkers for early ovarian cancer detection.Cell communication and signaling : CCS · 2026Article
- Diagnostic Value of CA-125 and Other Tumor Biomarkers in Children with Suspected Malignancy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- Clinical significance of differential plasma proteins levels in the diagnosis of epithelial ovarian cancer.World journal of experimental medicine · 2025Article
- A highly sensitive photoelectrochemical immunosensor for cancer antigen (CA 125) based on a nanoplatform of carbon dots and cadmium sulphide.RSC advances · 2025Article
- Redefined complement C3c structures have significant increase in the plasma of ovarian cancer patients.Journal of the Chinese Medical Association : JCMA · 2025Article
- The Evolving Landscape of Ovarian Cancer: Innovations in Biotechnology and Artificial Intelligence- Based Screening and Treatment.Current treatment options in oncology · 2025Review
- Review
- Prospects and challenges of deep learning in gynecologic malignancies.Frontiers in oncology · 2025Review
- Decoding the pathological and genomic profile of epithelial ovarian cancer.Scientific reports · 2024Article
- Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Comprehensive DNA methylation profiling by MeDIP-NGS identifies potential genes and pathways for epithelial ovarian cancer.Journal of ovarian research · 2024Article
- Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers.Cancers · 2023Review
- Circulating Biomarkers for Cancer Detection: Could Salivary microRNAs Be an Opportunity for Ovarian Cancer Diagnostics?Biomedicines · 2023Review
- Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable?Gynecologic oncology reports · 2023Article
- Application of Nonlinear Models Combined with Conventional Laboratory Indicators for the Diagnosis and Differential Diagnosis of Ovarian Cancer.Journal of clinical medicine · 2023Article
- A comprehensive overview of exosome lncRNAs: Emerging biomarkers and potential therapeutics in gynecological cancers.Frontiers in oncology · 2023Review
- Immunometabolic profiling of cervicovaginal lavages identifies key signatures associated with adenomyosis.iScience · 2022Article
- Space- and Time-Resolved Metabolomics of a High-Grade Serous Ovarian Cancer Mouse Model.Cancers · 2022Article
- Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery.Cancer biomarkers : section A of Disease markers · 2022Review
- Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) represents the most lethal gynecological cancer and the poor prognosis is often attributable to late diagnosis. The diagnostic approach to woman presenting with pelvic mass is difficult and differential diagnosis often requires invasive histological examination. Serum CA125 and HE4, as well as the most of the other serum biomarkers discovered and validated, are not sufficiently sensitive and specific to make early diagnosis. Moreover, conflicting results exist about the improvement of diagnostic performance by using multivariate index assays, developed by combining circulating biomarkers with other variables (i.e., ultrasound and/or menopausal status and/or age), in comparison to CA125 or HE4 alone. In the last years, several studies focused on the microRNAs (miRs), short single-stranded non-coding RNA that regulate several messenger RNAs (mRNAs). As in other cancer types, the aberrant miRs expression has been demonstrated in gynecological cancers, in both tissues and serum samples. In particular, the diagnostic performance of single or miRs panels resulted very high. However, to date, despite the potential clinical utility has been demonstrated, none of these miRs has been validated in large OC populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.